title: The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.
abstract: Kaposi's sarcoma-associated herpesvirus (KSHV) is causally related to Kaposi's sarcoma (KS), the most common malignancy in untreated individuals with HIV/AIDS. The adaptive T-cell immune response against KSHV has not been fully characterized. To achieve a better understanding of the antigenic repertoire of the CD8 and CD4 T-cell responses against KSHV, we constructed a library of lentiviral expression vectors each coding for one of 31 individual KSHV open reading frames (ORFs). We used these to transduce monocyte-derived dendritic cells (moDCs) isolated from 14 KSHV-seropositive (12 HIV-positive) and 7 KSHV-seronegative (4 HIV-positive) individuals. moDCs were transduced with up to 3 KSHV ORFs simultaneously (ORFs grouped according to their expression during the viral life cycle). Transduced moDCs naturally process the KSHV genes and present the resulting antigens in the context of MHC class I and II. Transduced moDCs were cultured with purified autologous T cells and the CD8 and CD4 T-cell proliferative responses to each KSHV ORF (or group) was assessed using a CFSE dye-based assay. Two pools of early lytic KSHV genes ([ORF8/ORF49/ORF61] and [ORF59/ORF65/K4.1]) were frequently-recognized targets of both CD8 and CD4 T cells from KSHV seropositive individuals. One pool of late lytic KSHV genes ([ORF28/ORF36/ORF37]) was a frequently-recognized CD8 target and another pool of late genes ([ORF33/K1/K8.1]) was a frequently-recognized CD4 target. We report that both the CD8 and CD4 T-cell responses against KSHV are skewed towards genes expressed in the early and late phases of the viral lytic cycle, and identify some previously unknown targets of these responses. This knowledge will be important to future immunological investigations into KSHV and may eventually lead to the development of better immunotherapies for KSHV-related diseases.
authors.affiliation: Department of Immunology, Imperial College London, London, United Kingdom.
authors.forename: Rebecca C
authors.initials: RC
authors.lastname: Robey
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Lagos
authors.forename: Fiona
authors.initials: F
authors.lastname: Gratrix
authors.forename: Stephen
authors.initials: S
authors.lastname: Henderson
authors.forename: Nick C
authors.initials: NC
authors.lastname: Matthews
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Vart
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
authors.forename: Chris
authors.initials: C
authors.lastname: Boshoff
authors.forename: Frances M
authors.initials: FM
authors.lastname: Gotch
mesh_terms: D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D049109:Cell Proliferation; D015331:Cohort Studies; D003713:Dendritic Cells / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000150:complications; D006566:Herpesviridae Infections / Q000150:complications / Q000378:metabolism*; D019288:Herpesvirus 8, Human / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism; D016366:Open Reading Frames
chemical_list: D000956:Antigens, Viral